(S)-3-t-butoxy-2-methylpropanal | 111955-97-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-3-t-butoxy-2-methylpropanal
• 英文别名: (2S)-2-methyl-3-[(2-methylpropan-2-yl)oxy]propanal
• CAS: 111955-97-6
• 化学式: C₈H₁₆O₂
• 分子量: 144.214
• InChiKey: LJQSELUIZOLLPW-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-3-t-butoxy-2-methylpropanal 在 咪唑 magnesium sulfate 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 60.0h， 生成 (3R,4S)-1-(di-p-anisylmethyl)-3-acetyl-4-<(R)-1-(t-butoxymethyl)ethyl>-2-azetidinone
  参考文献：
  名称：

  从（）-3-羟基-2-甲基丙酸甲酯合成一种新型高效合成1β-甲基卡巴培南抗生素关键中间体的方法

  摘要：

  从市售的3-羟基-2-甲基丙酸（）-甲酯开始，高效完成10步合成1β-甲基咔啉的关键中间体2的合成，总收率达到30％。探索的合成方案的特征在于，双烯酮与手性亚胺的加成反应是关键的非对映选择性步骤。

  DOI：

  10.1016/s0040-4039(00)85442-8

文献信息

• PEPTIDOMIMETIC COMPOUNDS AS IMMUNOMODULATORS
  申请人：AURIGENE DISCOVERY TECHNOLOGIES LIMITED

  公开号：US20130237580A1

  公开（公告）日：2013-09-12

  The present invention relates to novel peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

  本发明涉及作为治疗剂的新型肽类似物化合物，能够抑制程序性细胞死亡1（PD1）信号通路。该发明还涉及这些治疗剂的衍生物。该发明还包括利用所述治疗剂和衍生物治疗通过免疫增强来抑制由于PD-1、PD-L1或PD-L2引起的免疫抑制信号的障碍，并使用它们进行治疗的疗法。
• A novel and efficient synthesis of the key intermediate of 1β-methylcarbapenem antibiotics from ()-methyl 3-hydroxy-2-methylpropionate
  作者：Takeo Kawabata、Yoshikazu Kimura、Yoshio Ito、Shiro Terashima、Akira Sasaki、Makoto Sunagawa

  DOI：10.1016/s0040-4039(00)85442-8

  日期：1986.1

  A highly efficient synthesis of the key intermediate 2 of 1β-methylcarbapenems was accomplished in 10 steps and 30% overall yield starting from commercially available ()-methyl 3-hydroxy-2-methylpropionate. The explored synthetic scheme features the addition reaction of diketene with a chiral imine as a key diastereoselective step.

  从市售的3-羟基-2-甲基丙酸（）-甲酯开始，高效完成10步合成1β-甲基咔啉的关键中间体2的合成，总收率达到30％。探索的合成方案的特征在于，双烯酮与手性亚胺的加成反应是关键的非对映选择性步骤。
• Therapeutic Compounds for Immunomodulation
  申请人：Sasikumar Pottayil G. N.

  公开号：US20140199334A1

  公开（公告）日：2014-07-17

  The present invention provides Immunosuppressive compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signalling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides pharmaceutical compositions comprising the Immunosuppressive peptide compounds or modified peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

  本发明提供了能够抑制程序性细胞死亡1（PD1）信号通路的免疫抑制化合物。本发明还提供了基于肽的组合物，通过抑制由PD-1，PD-L1或PD-L2诱导的免疫抑制信号而引起免疫增强，用于治疗癌症或感染的治疗方法，包括作为活性成分的免疫增强底物。此外，本发明提供了包含免疫抑制肽化合物或修饰肽基团的药物组合物，用于预防和/或治疗癌症，癌症转移，免疫缺陷，传染病或类似疾病的预防性和/或治疗性剂，并将PD-1或PD-L1应用为测试或诊断剂或用于此类疾病的研究剂。
• KAWABATA, TAKEO;KIMURA, YOSHIKAZU;ITO, YOSHIO;TERASHIMA, SHIRO;SASAKI, AK+, TETRAHEDRON, 44,(1988) N 8, 2149-2165
  作者：KAWABATA, TAKEO、KIMURA, YOSHIKAZU、ITO, YOSHIO、TERASHIMA, SHIRO、SASAKI, AK+

  DOI：——

  日期：——
• IMMUNOSUPPRESSION MODULATING COMPOUNDS
  申请人：Sasikumar Pottayil G. N.

  公开号：US20110318373A1

  公开（公告）日：2011-12-29

  The present invention provides immunosuppression compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.